Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Industries is expected to achieve substantial revenue growth, with projected sales for Ajovy hitting $785 million in 2026, representing a 17% year-over-year increase, and Uzedy anticipated to reach $278 million, reflecting a remarkable 45% growth year-over-year. The company's strong performance in the market is further evidenced by Ajovy’s global revenues of $211 million, which exceeded expectations by 19%, driven by volume gains and improved pricing strategies. With ongoing shifts towards higher-value products and projected net savings of $700 million by 2027, Teva is well-positioned for significant expansion in cash flows and overall financial performance.

Bears say

Teva Pharmaceutical Industries faces significant challenges that contribute to a negative outlook, primarily driven by expected revenue declines due to inventory management and pricing pressures ahead of the Inflation Reduction Act (IRA) implementation. The company's generics segment reported a revenue miss of 3%, with a notable decline in US total prescriptions, indicating persistent market difficulties, while Austedo sales projections suggest a decline in 2027 despite earlier growth. Additionally, the company’s net debt remains a concern, with a ratio of 2.5x EBITDA alongside ongoing risks related to regulatory uncertainties, litigation, and the potential failure of pipeline initiatives.

Teva Pharmaceutical (TEVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.